XNCR · XBRL financial data

Xencor financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (XNCR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	122,694	275,111	164,579	174,615	110,493	125,576
Research and development	169,802	192,507	199,563	253,598	227,686	239,434
General and administrative	29,689	38,837	47,489	53,379	61,215	63,644
Total operating expenses	199,491	231,344	247,052	306,977	288,901	303,078
Operating income (loss)	(76,797)	43,767	(82,473)	(132,362)	(178,408)	(177,502)
Interest income	—	862	4,830	19,331	31,930	27,524
Interest expense	—	13	13	6,177	36,643	31,927
Other income (expense)	200	(1,274)	(286)	(31)	50	(73)
Income tax expense (benefit)	0	0	673	13,662	1,617	2,504
Net income (loss)	(69,333)	82,631	(55,181)	(133,133)	(232,618)	(91,923)
Earnings per share, basic USD per share	(1.21)	1.42	(0.93)	(2.20)	(3.58)	(1.24)
Earnings per share, diluted USD per share	(1.21)	1.37	(0.93)	(2.20)	(3.58)	(1.24)
Weighted average shares, basic thousands of shares	57,213	58,380	59,652	60,503	65,041	74,239
Weighted average shares, diluted thousands of shares	57,213	60,495	59,652	60,503	65,041	74,239

Fiscal years (XNCR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	163,544	143,480	53,942	53,790	40,875	54,073
Marketable securities	434,156	153,767	526,689	497,725	408,971	381,158
Accounts receivable	11,443	66,384	28,997	23,739	60,849	29,299
Prepaid and other current assets	10,726	23,877	23,283	18,139	18,977	22,789
Total current assets	637,672	424,368	675,342	635,603	577,601	599,821
Property and equipment, net	21,682	28,240	59,183	66,124	59,800	53,308
Right-of-use asset	10,600	31,730	34,419	33,995	38,341	37,592
Total assets	703,244	838,211	846,266	965,135	951,945	875,495
Accounts payable	8,954	14,001	10,088	13,914	16,759	10,828
Accrued liabilities	17,603	19,443	18,728	23,564	19,217	34,960
Total current liabilities	121,061	70,738	63,844	73,915	87,432	95,907
Long-term debt	—	—	0	161,772	115,159	76,482
Lease liability, non-current	9,739	33,969	54,926	59,025	65,338	64,735
Total liabilities	130,800	104,707	118,770	303,048	277,919	239,908
Accumulated deficit	(365,735)	(283,104)	(338,285)	(471,418)	(704,036)	(795,959)
Total stockholders' equity	572,444	733,504	727,496	661,750	677,611	635,587
Total liabilities and equity	703,244	838,211	846,266	965,135	951,945	875,495
Common shares outstanding (cover page) thousands of shares	57,945	59,375	60,030	61,120	70,462	73,339

Fiscal years (XNCR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(69,333)	82,631	(55,181)	(133,133)	(232,618)	(91,923)
Stock-based compensation	31,619	36,975	48,913	53,755	53,281	43,227
Depreciation and amortization	5,794	7,491	8,799	11,498	12,107	10,512
Net cash from operating activities	(5,004)	(16,853)	24,485	(77,926)	(202,188)	(135,117)
Purchases of property and equipment	10,539	13,299	38,494	18,448	6,097	3,150
Net cash from investing activities	100,192	(46,249)	(119,725)	(111,065)	(7,872)	139,985
Proceeds from issuing common stock	0	28,920	0	0	201,256	0
Net cash from financing activities	18,044	43,038	5,702	189,219	197,152	8,232
Net change in cash	113,232	(20,064)	(89,538)	228	(12,908)	13,100

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Evolus	41,700	77,952	(1,933)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Savara	41,800	not reported	(29,747)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384,036	65,414	(36,315)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	110,768	99,313	(60,841)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39,416	32,355	10,070	1.1B	—	Q1 FY27 10-QJun 30, 2026
Trevi Therapeutics	54,302	not reported	(17,429)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Stoke Therapeutics	107,271	11,255	(62,686)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
KalVista Pharmaceuticals	213,768	40,863	(14,455)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.